Company news
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) news
Tevogen Bio Holdings Inc. news releases on 6ix. Latest, Aug 18, 2025: Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery
Press releases — page 2
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery
August 18, 2025
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected
August 14, 2025
Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
August 13, 2025
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
August 11, 2025
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
August 11, 2025
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
August 11, 2025
REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
August 11, 2025
REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
August 8, 2025
Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy
August 7, 2025
Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
August 6, 2025
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
August 5, 2025
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
August 1, 2025
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
August 1, 2025
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
July 30, 2025
Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
July 28, 2025
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
July 18, 2025
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility
July 17, 2025
Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch
July 16, 2025
Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs
July 14, 2025
Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
July 10, 2025
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
June 30, 2025
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery
June 18, 2025
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
June 9, 2025
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
May 30, 2025
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow
May 23, 2025
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting
May 22, 2025
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
May 12, 2025
Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest
May 2, 2025
CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment
April 30, 2025
Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts
April 29, 2025
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
April 29, 2025
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion
April 28, 2025
Tevogen Bio Announces 2025 Annual Meeting
April 25, 2025
Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility
April 17, 2025
Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction
April 15, 2025
Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States
April 9, 2025
Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs
April 8, 2025
Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission
April 7, 2025
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
March 26, 2025
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
March 25, 2025
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
March 10, 2025
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
March 7, 2025
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
March 3, 2025
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
February 28, 2025
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
February 21, 2025
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
February 13, 2025
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
February 13, 2025
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
February 13, 2025
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
February 12, 2025
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure
February 6, 2025